Skip to main content Skip to search
+34 659 496 544

Genética y Terapia en Cáncer de Próstata

Publicaciones

2024

Esteban-Villarrubia, J, Ballesteros, PA, Martín-Serrano, M, Vico, MR, Funes, JM, de Velasco, G, Castro, E, Olmos, D, Castellano, D, González-Billalabeitia, E (2024).

Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

Immuno. Review. 4(4):444-460.
[doi:10.3390/immuno4040028]
Iglesias-Matesanz, P, Lacalle-Gonzalez, C, Lopez-Blazquez, C, Otieno, MO, Garcia-Foncillas, J, Martinez-Useros, J (2024).

Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment

Antioxidants. Review. 13(11).
[doi:10.3390/antiox13111405]
Montero-Hidalgo, AJ, Jiménez-Vacas, JM, Gómez-Gómez, E, Porcel-Pastrana, F, Sáez-Martinez, P, Pérez-Gómez, JM, Fuentes-Fayos, AC, Blázquez-Encinas, R, Sánchez-Sánchez, R, González-Serrano, T, Castro, E, López-Soto, PJ, Carrasco-Valiente, J, Sarmento-Cabral, A, Martinez-Fuentes, AJ, Eyras, E, Castaño, JP, Sharp, A, Olmos, D, Gahete, MD, Luque, RM (2024).

SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer

Science Advances. Article. 10(40).
[doi:10.1126/sciadv.ado8231]
Garcia-Ruiz, A, Macarro, C, Zacchi, F, Morales-Barrera, R, Grussu, F, Casanova-Salas, I, Sanguedolce, F, Gonzalez, M, Cresta-Morgado, P, de Albert, M, Garcia-Bennett, J, Marmolejo, D, Planas, J, Roche, S, Mast, R, Zatse, C, Piulats, JM, Herrera-Imbroda, B, Regis, L, Agundez, L, Olmos, D, Calvo, N, Escobar, M, Carles, J, Mateo, J, Perez-Lopez, R (2024).

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

EUROPEAN UROLOGY. Editorial Material. 86(3):272-274.
[doi:10.1016/j.eururo.2024.02.016]
Roubaud, G, Attard, G, Boegemann, M, Olmos, D, Trevisan, M, Antoni, L, Pascoe, K, Capone, C, Van Sanden, S, Hashim, M, Palmer, S, Chi, K (2024).

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer

EUROPEAN JOURNAL OF CANCER. Article. 209.
[doi:10.1016/j.ejca.2024.114183]
del Cañizo, CG, Ginel, IG, Arroba, CMA, Moreno, AD, Arroyo, MH, Antolin, AR, Ramos, FG (2024).

Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 42(8):24615-24621.
[doi:10.1016/j.urolonc.2024.03.014]
Romero-Laorden, N, Lorente, D, de Velasco, G, Lozano, R, Herrera, B, Puente, J, López, PP, Medina, A, Almagro, E, Gonzalez-Billalabeitia, E, Villla-Guzman, JC, González-del-Alba, A, Borrega, P, Laínez, N, Fernández-Freire, A, Hernández, A, Rodriguez-Vida, A, Chirivella, I, Fernandez-Parra, E, López-Campos, F, Pacheco, MI, Morales-Barrera, R, Fernández, O, Villatoro, R, Luque, R, Hernando, S, Castellano, DC, Castro, E, Olmos, D (2024).

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

European Urology Oncology. Article. 7(3):447-455.
[doi:10.1016/j.euo.2023.09.015]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Apr, 10.1007/s40265-024-02030-7, 2024)

DRUGS. Correction. 84(5):621-621.
[doi:10.1007/s40265-024-02044-1]
Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

DRUGS. Review. 84(5):527-548.
[doi:10.1007/s40265-024-02030-7]
Mateo, J, de Bono, JS, Fizazi, K, Saad, F, Shore, N, Sandhu, S, Chi, KN, Agarwal, N, Olmos, D, Thiery-Vuillemin, A, Özgüroglu, M, Mehra, N, Matsubara, N, Joung, JY, Padua, C, Korbenfeld, E, Kang, JY, Marshall, H, Lai, ZW, Barnicle, A, Poehlein, C, Lukashchuk, N, Hussain, M (2024).

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(5).
[doi:10.1200/JCO.23.00339]
Nunes, SP, Morales, L, Rubio, C, Munera-Maravilla, E, Lodewijk, I, Suárez-Cabrera, C, Martínez, VG, Pérez-Escavy, M, Pérez-Crespo, M, Sánchez, MA, Montesinos, E, San José-Enériz, E, Agirre, X, Prósper, F, Pineda-Lucena, A, Henrique, R, Dueñas, M, Correia, MP, Jerónimo, C, Paramio, JM (2024).

Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

Cell Death Discovery. Article. 10(1).
[doi:10.1038/s41420-023-01786-3]

2023

Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]
Esteban-Villarrubia, J, Ferreiro, CR, Carril-Ajuria, L, Carretero-González, A, Iacovelli, R, Albiges, L, Castellano, D, de Velasco, G (2023).

Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 41(9).
[doi:10.1016/j.urolonc.2023.05.002]
Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]
Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.
Chi, KN, Rathkopf, D, Smith, MR, Efstathiou, E, Attard, G, Olmos, D, Lee, JY, Small, EJ, Pereira de Santana Gomes AJ, Roubaud, G, Saad, M, Zurawski, B, Sakalo, V, Mason, GE, Francis, P, Wang G, Wu, D, Diorio, B, Lopez-Gitlitz, A, Sandhu, S (2023).

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(18):3339.
[doi:10.1200/JCO.22.01649]
Matsubara, N, de Bono, J, Sweeney, C, Chi, KN, Olmos, D, Sandhu, S, Massard, C, Garcia, J, Chen, G, Harris, A, Schenkel, F, Sane, R, Hinton, H, Bracarda, S, Sternberg, CN (2023).

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer

CLINICAL GENITOURINARY CANCER. Article. 21(2):230.
[doi:10.1016/j.clgc.2023.01.001]
Esteban-Villarrubia, J, Torres-Jiménez, J, Bueno-Bravo, C, García-Mondaray, R, Subiela, JD, Gajate, P (2023).

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer

Cancers. Review. 15(3).
[doi:10.3390/cancers15030566]
Chi, KN, Barnicle, A, Sibilla, C, Lai, ZW, Corcoran, C, Barrett, JC, Adelman, CA, Qiu, P, Easter, A, Dearden, S, Oxnard, GR, Agarwal, N, Azad, A, de Bono, J, Mateo, J, Olmos, D, Thiery-Vuillemin, A, Harrington, EA (2023).

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.

CLINICAL CANCER RESEARCH. Article. 29(1):81-91.
[doi:10.1158/1078-0432.CCR-22-0931]